Recent developments in liver pathology

Archives of Pathology and Laboratory Medicine

Volumn 133, Issue 7, 2009, Pages 1078-1086

  Yan, Benjamin C ^a   Hart, John A ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; BETA CATENIN; C REACTIVE PROTEIN; CYTOCHROME P450C17; ESTROGEN; FATTY ACID BINDING PROTEIN; FERROPORTIN; GLUTAMATE AMMONIA LIGASE; HAPTOGLOBIN; HEMOGLOBIN; HEMOJUVELIN; HEPATOCYTE NUCLEAR FACTOR 1BETA; HEPCIDIN; INTERLEUKIN 6; IRON; ORAL CONTRACEPTIVE AGENT; RALOXIFENE; STAT3 PROTEIN; TAMOXIFEN; TRANSFERRIN RECEPTOR 2; TUMOR MARKER;

CANCER EPIDEMIOLOGY; CHILDHOOD DISEASE; DISEASE PREDISPOSITION; ERYTHROPOIESIS; FATTY LIVER; GENE LOCUS; GENE MUTATION; GENETIC POLYMORPHISM; HEMOCHROMATOSIS; HETEROZYGOSITY LOSS; HUMAN; INFLAMMATION; IRON ABSORPTION; IRON METABOLISM; JUVENILE HEMOCHROMATOSIS; LIVER; LIVER ADENOMA; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALIGNANT TRANSFORMATION; MEDICAL LITERATURE; MEDICAL SCHOOL; MICROSATELLITE MARKER; MOLECULAR GENETICS; NODULAR HYPERPLASIA; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATION REDUCTION REACTION; PATHOLOGY; PERSONAL EXPERIENCE; PREVALENCE; REVIEW; SEX RATIO; SIGNAL TRANSDUCTION; TELANGIECTASIA; TUMOR VOLUME;

ADENOMA; ADOLESCENT; ADULT; CARCINOMA, HEPATOCELLULAR; CHILD; CHILD, PRESCHOOL; FATTY LIVER; HEMOCHROMATOSIS; HUMANS; LIVER NEOPLASMS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 67649815154     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Review

References (119)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Nguyen BN, Flejou JF, Terris B, Belghiti J, Degott C. Focal nodular hyperplasia of the liver: a comprehensive pathologic study of 305 lesions and recognition of new histologic forms. Am J Surg Pathol. 1999;23:1441-1454.
3. Bioulac-Sage P, Rebouissou S, Sa Cunha A, et al. Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver. Gastroenterology. 2005;128:1211-1218. (Pubitemid 40712173)
4. Zucman-Rossi J, Jeannot E, Nhieu JT, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology. 2006;43:515-524.
5. Zucman-Rossi J. Genetic alterations in hepatocellular adenomas: recent findings and new challenges. J Hepatol. 2004;40:1036-1039. (Pubitemid 38670142)
6. Wanless IR, Albrecht S, Bilbao J, et al. Multiple focal nodular hyperplasia of the liver associated with vascular malformations of various organs and neoplasia of the brain: a new syndrome. Mod Pathol. 1989;2:456-462.
7. Lepreux S, Laurent C, Le Bail B, Saric J, Balabaud C, Bioulac-Sage P. Multiple telangiectatic focal nodular hyperplasia: vascular abnormalities. Virchows Arch. 2003;442:226-230. (Pubitemid 36399215)
8. Attal P, Vilgrain V, Brancatelli G, et al. Telangiectatic focal nodular hyperplasia: US, CT, and MR imaging findings with histopathologic correlation in 13 cases. Radiology. 2003;228:465-472. (Pubitemid 36910089)
9. Paradis V, Laurent A, Flejou JF, Vidaud M, Bedossa P. Evidence for the polyclonal nature of focal nodular hyperplasia of the liver by the study of X-chromosome inactivation. Hepatology. 1997;26:891-895. (Pubitemid 27413654)
10. Paradis V, Benzekri A, Dargere D, et al. Telangiectatic focal nodular hyperplasia: a variant of hepatocellular adenoma. Gastroenterology. 2004;126: 1323-1329. (Pubitemid 38559002)
11. Bluteau O, Jeannot E, Bioulac-Sage P, et al. Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat Genet. 2002;32:312-315.
12. Chen YW, Jeng YM, Yeh SH, Chen PJ. P53 gene and Wnt signaling in benign neoplasms: beta-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia. Hepatology. 2002;36:927-935.
13. Takayasu H, Motoi T, Kanamori Y, et al. Two case reports of childhood liver cell adenomas harboring beta-catenin abnormalities. Hum Pathol. 2002;33:852-855. (Pubitemid 34983108)
14. Torbenson M, Lee JH, Choti M, et al. Hepatic adenomas: analysis of sex steroid receptor status and the Wnt signaling pathway. Mod Pathol. 2002;15:189-196. (Pubitemid 34246615)
15. Yamamoto Y, Sakamoto M, Fujii G, et al. Overexpression of orphan Gprotein- coupled receptor, Gpr49, in human hepatocellular carcinomas with betacatenin mutations. Hepatology. 2003;37:528-533. (Pubitemid 36258773)
16. Cadoret A, Ovejero C, Terris B, et al. New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism. Oncogene. 2002;21:8293-8301. (Pubitemid 35477869)
17. Rebouissou S, Imbeaud S, Balabaud C, et al. HNF1alpha inactivation promotes lipogenesis in human hepatocellular adenoma independently of SREBP-1 and carbohydrate-response element-binding protein (ChREBP) activation. J Biol Chem. 2007;282:14437-14446. (Pubitemid 47100455)
18. Laurent-Puig P, Legoix P, Bluteau O, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology. 2001;120:1763-1773. (Pubitemid 32523494)
19. Nhieu JT, Renard CA, Wei Y, Cherqui D, Zafrani ES, Buendia MA. Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol. 1999;155:703-710. (Pubitemid 29426815)
20. de La Coste A, Romagnolo B, Billuart P, et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA. 1998;95:8847-8851. (Pubitemid 28350577)
21. Miyoshi Y, Iwao K, Nagasawa Y, et al. Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res 1998;58:2524-2527. (Pubitemid 28275419)
22. Tward AD, Jones KD, Yant S, et al. Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc Natl Acad Sci USA. 2007; 104:14771-14776. (Pubitemid 350003218)
23. Bioulac-Sage P, Rebouissou S, Thomas C, et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology. 2007;46:740-748. (Pubitemid 47436120)
24. Goldstein S, Meyerstein D, Czapski G. The fenton reagents. Free Radic Biol Med. 1993;15:435-445. (Pubitemid 23283560)
25. Halliwell B, Gutteridge JM. Free Radicals in Biology and Medicine. 2nd ed. Oxford, United Kingdom: Oxford University Press; 1989.
26. Aruoma OI, Halliwell B, Dizdaroglu M. Iron ion-dependent modification of bases in DNA by the superoxide radical-generating system hypoxanthine/xanthine oxidase. J Biol Chem. 1989;264:13024-13028. (Pubitemid 19194876)
27. Aruoma OI, Halliwell B, Gajewski E, Dizdaroglu M. Damage to the bases in DNA induced by hydrogen peroxide and ferric ion chelates. J Biol Chem. 1989; 264:20509-20512. (Pubitemid 20009240)
28. Haber F, Weiss J. The catalytic decomposition of hydrogen peroxide by iron salts. Proc R Soc Lond A Math Phys Sci. 1934;147:332-351.
29. Torti FM, Torti SV. Regulation of ferritin genes and protein. Blood. 2002; 99:3505-3516. (Pubitemid 34534516)
30. Harrison PM. Ferritin: an iron-storage molecule. Semin Hematol. 1977;14: 55-70.
31. Cheng Y, Zak O, Aisen P, Harrison SC, Walz T. Structure of the human transferrin receptor-transferrin complex. Cell. 2004;116:565-576. (Pubitemid 38264433)
32. Fleming MD, Trenor CC III, Su MA, et al. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat Genet. 1997;16: 383-386. (Pubitemid 27323306)
33. Gunshin H, Mackenzie B, Berger UV, et al. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature. 1997;388:482-488. (Pubitemid 27328927)
34. Kozyraki R, Fyfe J, Verroust PJ, et al. Megalin-dependent cubilin-mediated endocytosis is a major pathway for the apical uptake of transferrin in polarized epithelia. Proc Natl Acad Sci USA. 2001;98:12491-12496. (Pubitemid 33019973)
35. Kristiansen M, Graversen JH, Jacobsen C, et al. Identification of the haemoglobin scavenger receptor. Nature. 2001;409:198-201. (Pubitemid 32144285)
36. Abboud S, Haile DJ. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem. 2000;275:19906-19912. (Pubitemid 30441595)
37. Donovan A, Brownlie A, Zhou Y, et al. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature. 2000;403: 776-781. (Pubitemid 30111839)
38. McKie AT, Marciani P, Rolfs A, et al. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell. 2000;5:299-309. (Pubitemid 30628088)
39. Donovan A, Lima CA, Pinkus JL, et al. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab. 2005;1:191-200. (Pubitemid 43960600)
40. Harris ZL, Durley AP, Man TK, Gitlin JD. Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. Proc Natl Acad Sci USA. 1999;96:10812-10817. (Pubitemid 29442226)
41. Roetto A, Papanikolaou G, Politou M, et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet. 2003; 33:21-22. (Pubitemid 36068676)
42. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001;276:7806-7810. (Pubitemid 37385573)
43. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004; 306:2090-2093. (Pubitemid 40007660)
44. Nicolas G, Viatte L, Lou DQ, et al. Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis. Nat Genet. 2003;34: 97-101. (Pubitemid 36548798)
45. Nicolas G, Bennoun M, Porteu A, et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci USA. 2002;99: 4596-4601. (Pubitemid 34286030)
46. Nicolas G, Bennoun M, Devaux I, et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci USA. 2001;98:8780-8785. (Pubitemid 32678104)
47. Nemeth E, Roetto A, Garozzo G, Ganz T, Camaschella C. Hepcidin is decreased in TFR2 hemochromatosis. Blood. 2005;105:1803-1806. (Pubitemid 40223705)
48. Papanikolaou G, Samuels ME, Ludwig EH, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet. 2004;36:77-82. (Pubitemid 38056211)
49. Bridle KR, Frazer DM, Wilkins SJ, et al. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet. 2003;361:669-673. (Pubitemid 36246550)
50. Pietrangelo A, Dierssen U, Valli L, et al. STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo. Gastroenterology. 2007;132:294-300. (Pubitemid 46108739)
51. Verga Falzacappa MV, Vujic Spasic M, Kessler R, Stolte J, Hentze MW, Muckenthaler MU. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood. 2007;109:353-358. (Pubitemid 46053077)
52. Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood. 2006;108:3204-3209. (Pubitemid 44776963)
53. Rivera S, Gabayan V, Ganz T. In chronic inflammation, there exists an IL-6 independent pathway for the induction of hepcidin [abstract]. Blood. 2004; 104:875a.
54. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996;13:399-408. (Pubitemid 26256612)
55. Bennett MJ, Lebron JA, Bjorkman PJ. Crystal structure of the hereditary haemochromatosis protein HFE complexed with transferrin receptor. Nature. 2000;403:46-53. (Pubitemid 30038514)
56. Ikuta K, Fujimoto Y, Suzuki Y, et al. Overexpression of hemochromatosis protein, HFE, alters transferrin recycling process in human hepatoma cells. Biochim Biophys Acta. 2000;1496:221-231. (Pubitemid 30193221)
57. Lebron JA, Bennett MJ, Vaughn DE, et al. Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor. Cell. 1998;93:111-123. (Pubitemid 28173557)
58. Feder JN, Tsuchihashi Z, Irrinki A, et al. The hemochromatosis founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell surface expression. J Biol Chem. 1997;272:14025-14028. (Pubitemid 27232800)
59. Waheed A, Parkkila S, Zhou XY, et al. Hereditary hemochromatosis: effects of C282Y and H63D mutations on association with beta2-microglobulin, intracellular processing, and cell surface expression of the HFE protein in COS-7 cells. Proc Natl Acad Sci USA. 1997;94:12384-12389. (Pubitemid 27492537)
60. Hanson EH, Imperatore G, Burke W. HFE gene and hereditary hemochromatosis: a HuGE review-Human Genome Epidemiology. Am J Epidemiol. 2001; 154:193-206.
61. Asberg A, Thorstensen K, Hveem K, Bjerve KS. Hereditary hemochromatosis: the clinical significance of the S65C mutation. Genet Test. 2002;6:59-62. (Pubitemid 34620116)
62. Gochee PA, Powell LW, Cullen DJ, Du Sart D, Rossi E, Olynyk JK. A population- based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. Gastroenterology. 2002;122:646-651. (Pubitemid 34173816)
63. Holmstrom P, Marmur J, Eggertsen G, Gafvels M, Stal P. Mild iron overload in patients carrying the HFE S65C gene mutation: a retrospective study in patients with suspected iron overload and healthy controls. Gut. 2002;51:723-730. (Pubitemid 35216863)
64. Mura C, Raguenes O, Ferec C. HFE mutations analysis in 711 hemochromatosis probands: evidence for S65C implication in mild form of hemochromatosis. Blood. 1999;93:2502-2505. (Pubitemid 29181181)
65. Yip R. Iron deficiency. Bull World Health Organ. 1998;76(suppl 2):121-123.
66. Finch SC, Finch CA. Idiopathic hemochromatosis, an iron storage disease: A, iron metabolism in hemochromatosis. Medicine (Baltimore). 1955;34:381-430.
67. Niederau C, Fischer R, Purschel A, StremmelW, Haussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology. 1996;110:1107-1119. (Pubitemid 26113751)
68. Fargion S, Mandelli C, Piperno A, et al. Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis. Hepatology. 1992;15:655-659.
69. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med. 1985;313:1256-1262. (Pubitemid 16217048)
70. Cogswell ME, McDonnell SM, Khoury MJ, Franks AL, BurkeW, Brittenham G. Iron overload, public health, and genetics: evaluating the evidence for hemochromatosis screening. Ann Intern Med. 1998;129:971-979. (Pubitemid 28549835)
71. Eason RJ, Adams PC, Aston CE, Searle J. Familial iron overload with possible autosomal dominant inheritance. Aust N Z J Med. 1990;20:226-230. (Pubitemid 20283040)
72. Lamon JM, Marynick SP, Roseblatt R, Donnelly S. Idiopathic hemochromatosis in a young female: a case study and review of the syndrome in young people. Gastroenterology. 1979;76:178-183. (Pubitemid 9129528)
73. Montosi G, Donovan A, Totaro A, et al. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest. 2001;108:619-623. (Pubitemid 32777742)
74. Njajou OT, Vaessen N, Joosse M, et al. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat Genet. 2001;28:213-214. (Pubitemid 32626019)
75. Camaschella C, Roetto A, Cali A, et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet. 2000;25:14-15. (Pubitemid 30257027)
76. De Gobbi M, Roetto A, Piperno A, et al. Natural history of juvenile haemochromatosis. Br J Haematol. 2002;117:973-979. (Pubitemid 34649342)
77. Kuninger D, Kuns-Hashimoto R, Kuzmickas R, Rotwein P. Complex biosynthesis of the muscle-enriched iron regulator RGMc. J Cell Sci. 2006;119: 3273-3283. (Pubitemid 44405213)
78. Lee PL, Beutler E, Rao SV, Barton JC. Genetic abnormalities and juvenile hemochromatosis: mutations of the HJV gene encoding hemojuvelin. Blood. 2004;103:4669-4671. (Pubitemid 38746001)
79. Schmidtmer J, Engelkamp D. Isolation and expression pattern of three mouse homologues of chick Rgm. Gene Expr Patterns. 2004;4:105-110. (Pubitemid 37498301)
80. Lin L, Goldberg YP, Ganz T. Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin. Blood. 2005;106:2884-2889. (Pubitemid 41510769)
81. Xia Y, Babitt JL, Sidis Y, Chung RT, Lin HY. Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin. Blood. 2008;111:5195-5204.
82. Babitt JL, Huang FW, Xia Y, Sidis Y, Andrews NC, Lin HY. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest. 2007;117:1933-1939. (Pubitemid 47036327)
83. Truksa J, Peng H, Lee P, Beutler E. Bone morphogenetic proteins 2, 4, and 9 stimulate murine hepcidin 1 expression independently of Hfe, transferrin receptor 2 (Tfr2), and IL-6. Proc Natl Acad Sci USA. 2006;103:10289-10293. (Pubitemid 44051159)
84. Babitt JL, Huang FW, Wrighting DM, et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet. 2006;38: 531-539.
85. Zhang AS, Anderson SA, Meyers KR, Hernandez C, Eisenstein RS, Enns CA. Evidence that inhibition of hemojuvelin shedding in response to iron is mediated through neogenin. J Biol Chem. 2007;282:12547-12556. (Pubitemid 47100643)
86. Kuninger D, Kuns-Hashimoto R, Nili M, Rotwein P. Pro-protein convertases control the maturation and processing of the iron-regulatory protein, RGMc/hemojuvelin. BMC Biochem. 2008;9:9. (Pubitemid 351551355)
87. Silvestri L, Pagani A, Camaschella C. Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis. Blood. 2008; 111:924-931.
88. Choi SO, Cho YS, Kim HL, Park JW. ROS mediate the hypoxic repression of the hepcidin gene by inhibiting C/EBPalpha and STAT-3. Biochem Biophys Res Commun. 2007;356:312-317. (Pubitemid 46413166)
89. Nicolas G, Chauvet C,Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002;110:1037-1044.
90. Peyssonnaux C, Zinkernagel AS, Schuepbach RA, et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest. 2007;117:1926-1932. (Pubitemid 47036326)
91. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289:76-79.
92. Daniels SR. Regulation of body mass and management of childhood overweight. Pediatr Blood Cancer. 2005;44:589-594. (Pubitemid 40629206)
93. Dietz WH. Overweight in childhood and adolescence. N Engl J Med. 2004;350:855-857. (Pubitemid 38252530)
94. Wang G, Dietz WH. Economic burden of obesity in youths aged 6 to 17 years: 1979-1999. Pediatrics. 2002;109:e81. doi:10.1542/peds.109.5.e81.
95. Patton HM, Sirlin C, Behling C, Middleton M, Schwimmer JB, Lavine JE. Pediatric nonalcoholic fatty liver disease: a critical appraisal of current data and implications for future research. J Pediatr Gastroenterol Nutr. 2006;43:413-427. (Pubitemid 44568999)
96. International Diabetes Federation. http://www.idf.org. Accessed June 6, 2008.
97. Alberti KG. Impaired glucose tolerance: what are the clinical implications? Diabetes Res Clin Pract. 1998;40(suppl):3S-8S. (Pubitemid 28370883)
98. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006;118:1388-1393. (Pubitemid 46393782)
99. Schwimmer JB, McGreal N, Deutsch R, Finegold MJ, Lavine JE. Influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents. Pediatrics. 2005;115:e561-e565. doi:10.1542/peds.2004-1832. (Pubitemid 43843214)
100. Schwimmer JB, Behling C, Newbury R, et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology. 2005;42:641-649. (Pubitemid 41233657)
101. Schwimmer JB, Deutsch R, Rauch JB, Behling C, Newbury R, Lavine JE. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr. 2003;143:500-505. (Pubitemid 37352510)
102. Manton ND, Lipsett J, Moore DJ, Davidson GP, Bourne AJ, Couper RT. Non-alcoholic steatohepatitis in children and adolescents. Med J Aust. 2000;173: 476-479. (Pubitemid 30818434)
103. Rashid M, Roberts EA. Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr. 2000;30:48-53. (Pubitemid 30349945)
104. Baldridge AD, Perez-Atayde AR, Graeme-Cook F, Higgins L, Lavine JE. Idiopathic steatohepatitis in childhood: a multicenter retrospective study. J Pediatr. 1995;127:700-704.
105. Moran JR, Ghishan FK, Halter SA, Greene HL. Steatohepatitis in obese children: a cause of chronic liver dysfunction. Am J Gastroenterol. 1983;78:374-377.
106. Kirsch R, Clarkson V, Shephard EG, et al. Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies. J Gastroenterol Hepatol. 2003;18:1272-1282. (Pubitemid 37464002)
107. Djouadi F, Weinheimer CJ, Saffitz JE, et al. A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator-activated receptor alpha-deficient mice. J Clin Invest. 1998;102:1083-1091. (Pubitemid 28436268)
108. Kotoh K, Nakamuta M, Fukushima M, Morizono S, Enjoji M, Nawata H. Fertile females with nonalcoholic fatty liver disease (NAFLD) have higher levels of ALT than postmenopausal females: implications for the influence of fertility on NAFLD. Hepatogastroenterology. 2007;54:224-228. (Pubitemid 46511680)
109. Hewitt KN, Pratis K, Jones ME, Simpson ER. Estrogen replacement reverses the hepatic steatosis phenotype in the male aromatase knockout mouse. Endocrinology. 2004;145:1842-1848. (Pubitemid 38402393)
110. Nemoto Y, Toda K, Ono M, et al. Altered expression of fatty acid-metabolizing enzymes in aromatase-deficient mice. J Clin Invest. 2000;105:1819-1825. (Pubitemid 30421763)
111. Takamura T, Shimizu A, Komura T, et al. Selective estrogen receptor modulator raloxifene-associated aggravation of nonalcoholic steatohepatitis. Intern Med. 2007;46:579-581. (Pubitemid 46845850)
112. Oien KA, Moffat D, Curry GW, et al. Cirrhosis with steatohepatitis after adjuvant tamoxifen. Lancet. 1999;353:36-37. (Pubitemid 29037704)
113. Ogawa Y, Murata Y, Nishioka A, Inomata T, Yoshida S. Tamoxifen-induced fatty liver in patients with breast cancer. Lancet. 1998;351:725. (Pubitemid 28105346)
114. Van Hoof M, Rahier J, Horsmans Y. Tamoxifen-induced steatohepatitis. Ann Intern Med. 1996;124:855-856. (Pubitemid 26128420)
115. Pinto HC, Baptista A, Camilo ME, de Costa EB, Valente A, de Moura MC. Tamoxifen-associated steatohepatitis-report of three cases. J Hepatol. 1995;23: 95-97.
116. Pratt DS, Knox TA, Erban J. Tamoxifen-induced steatohepatitis. Ann Intern Med. 1995;123:236.
117. Maffei L, Murata Y, Rochira V, et al. Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. J Clin Endocrinol Metab. 2004;89:61-70. (Pubitemid 38183860)
118. Ohnishi T, Ogawa Y, Saibara T, et al. CYP17 polymorphism and tamoxifen-induced hepatic steatosis. Hepatol Res. 2005;33:178-180. (Pubitemid 41799800)
119. Ohnishi T, Ogawa Y, Saibara T, et al. CYP17 polymorphism as a risk factor of tamoxifen-induced hepatic steatosis in breast cancer patients. Oncol Rep. 2005;13:485-489.